Asset Details
Do you wish to reserve the book?
Human Papillomavirus–Attributable Cancers — United States, 2012–2016
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Human Papillomavirus–Attributable Cancers — United States, 2012–2016
Do you wish to request the book?
Human Papillomavirus–Attributable Cancers — United States, 2012–2016
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Human Papillomavirus–Attributable Cancers — United States, 2012–2016
2019
Overview
Human papillomavirus (HPV) causes nearly all cervical cancers and some cancers of the vagina, vulva, penis, anus, and oropharynx (1).* Most HPV infections are asymptomatic and clear spontaneously within 1 to 2 years; however, persistent infection with oncogenic HPV types can lead to development of precancer or cancer (2). In the United States, the 9-valent HPV vaccine (9vHPV) is available to protect against oncogenic HPV types 16, 18, 31, 33, 45, 52, and 58 as well as nononcogenic types 6 and 11 that cause genital warts. CDC analyzed data from the U.S. Cancer Statistics (USCS)
to assess the incidence of HPV-associated cancers and to estimate the annual number of cancers caused by HPV, overall and by state, during 2012-2016 (3,4). An average of 43,999 HPV-associated cancers were reported annually, and an estimated 34,800 (79%) of those cancers were attributable to HPV. Of these 34,800 cancers, an estimated 32,100 (92%) were attributable to the types targeted by 9vHPV, with 19,000 occurring among females and 13,100 among males. The most common were cervical (9,700) and oropharyngeal cancers (12,600). The number of cancers estimated to be attributable to the types targeted by 9vHPV ranged by state from 40 to 3,270 per year. HPV vaccination is an important strategy that could prevent these cancers, but during 2018, only half of adolescents were up to date on HPV vaccination (5). These surveillance data from population-based cancer registries can be used to inform the planning for, and monitor the long-term impact of, HPV vaccination and cancer screening efforts nationally and within states.
Publisher
Centers for Disease Control & Prevention (CDC),U.S. Government Printing Office,U.S. Center for Disease Control,Centers for Disease Control and Prevention
Subject
/ Anus Neoplasms - epidemiology
/ Cancer
/ Cervix
/ Female
/ HIV
/ Human immunodeficiency virus
/ Humans
/ Male
/ Oropharyngeal Neoplasms - epidemiology
/ Oropharyngeal Neoplasms - virology
/ Papillomavirus Infections - complications
/ Papillomavirus Vaccines - administration & dosage
/ Penile Neoplasms - epidemiology
/ Penis
/ United States - epidemiology
/ Uterine Cervical Neoplasms - epidemiology
/ Uterine Cervical Neoplasms - virology
/ Vaccines
/ Vagina
/ Vaginal Neoplasms - epidemiology
/ Vaginal Neoplasms - virology
/ Vulva
/ Vulvar Neoplasms - epidemiology
/ Warts
